Life sciences focused fund has executed three investments to date
Luxembourg-Strassen, June 25, 2019 – Vesalius Biocapital III (‘Vesalius’), the specialist life sciences venture capital investor, announces the final close of the VBC III fund securing EUR 120 million of equity commitments. This includes commitments of EUR 30 million from the European Investment Fund (EIF) and new and existing investors from Europe, the Americas and MENA. The fund is a validation of Vesalius’ proven approach to invest in later-stage European life sciences companies, providing capital to support their development. Vesalius Biocapital III has executed three investments to date.